- Home
- NTIP vs BCTX Comparison
NTIP vs BCTX Comparison
Compare NTIP & BCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NTIP | BCTX |
|---|---|---|
| Founded | 1990 | 2014 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Multi-Sector Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 33.3M | 28.8M |
| IPO Year | 2013 | 2025 |
Fundamental Metrics
Financial Performance| Metric | NTIP | BCTX |
|---|---|---|
| Price | $1.46 | $3.89 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $40.00 |
| AVG Volume (30 Days) | 34.3K | ★ 159.3K |
| Earning Date | 05-08-2026 | 03-10-2026 |
| Dividend Yield | ★ 6.85% | N/A |
| EPS Growth | ★ 15.38 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $150,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $380.95 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 50.00 | N/A |
| 52 Week Low | $1.16 | $0.61 |
| 52 Week High | $1.66 | $14.68 |
Technical Indicators
Market Signals| Indicator | NTIP | BCTX |
|---|---|---|
| Relative Strength Index (RSI) | 51.31 | 42.59 |
| Support Level | $1.34 | $3.66 |
| Resistance Level | $1.47 | $4.56 |
| Average True Range (ATR) | 0.11 | 0.28 |
| MACD | 0.00 | -0.06 |
| Stochastic Oscillator | 39.58 | 18.42 |
Price Performance
Historical ComparisonAbout NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.